Evidence map›Paper›PMID 30101418›Full record

ArticleClinical pharmacology and therapeutics2018

The Way Forward for Mechanism-Based Therapeutics in Genetically Defined Neurodevelopmental Disorders.

Meera E Modi, Mustafa Sahin

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Treating Rett syndrome: from mouse models to human therapies.Mammalian genome : official journal of the International Mammalian Genome Society · 2019
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Meera E ModiTranslational Neuroscience Center, F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mustafa SahinTranslational Neuroscience Center, F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-7044-2953

Funding

Toward better characterization and clinical trial readiness for targeting neuropsychiatric manifestations in PTEN pathogenic variantsU54NS092090 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI M. Pilar Trelles · 2014 to 2026
$20.1M
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous SclerosisU01NS082320 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI KRUEGER, DARCY, SAHIN, MUSTAFA · 2012 to 2018
$13.3M
Preventing Epilepsy using Vigabatrin in Infants with Tuberous Sclerosis ComplexU01NS092595 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BEBIN, MARTINA · 2016 to 2020
$7.1M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI POMEROY, SCOTT LOREN · 2016 to 2020
$5.2M
NICHD NIH HHS U54 HD090255NINDS NIH HHS U01 NS082320NINDS NIH HHS U01 NS092595NINDS NIH HHS U54 NS092090
6 · The paper itself

Abstract

Rare genetically defined neurodevelopmental disorders with increased risk of autism have recently become an entry point for autism-related drug discovery. Through exploration of downstream effects of the pathological mutations, specific mechanistic pathways have been identified as dysregulated. The identification of shared mechanisms across forms of autism opens the door for the development of novel "mechanism-based therapeutics." However, confidence in the therapeutic mechanism does not diminish the need for well-designed clinical trials.

Indexed as

MutationAdolescentAdolescent BehaviorAdolescent DevelopmentAge FactorsBrainCentral Nervous System AgentsChildChild BehaviorChild DevelopmentFragile X SyndromeGenetic Predisposition to DiseaseHumansNeurodevelopmental DisordersPhenotypeRett SyndromeCentral Nervous System Agents

Identifiers

PMID30101418
PMCPMC6175613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.